Clinical trials
Idiopathic Inflammatory Myopathies clinical trials
Below are recruiting idiopathic inflammatory myopathies clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT06698796RecruitingPhase 3
Study of dazukibart for ongoing idiopathic inflammatory myopathies
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
Glendale, ArizonaAges 18 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT05895786RecruitingPhase 3
Study drug for active dermatomyositis or polymyositis
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Glendale, ArizonaAges 18 years+ - NCT07374107Recruiting
Patient insights for shaping myositis research
This study asks people with autoimmune muscle diseases (myositis) and their caregivers to share their experiences and insights. By joining, you help shape better research and care for myositis.
New Orleans, LouisianaAges 7 years+ - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic inflammatory myopathies?
- Yes. Clin2 currently lists 45 recruiting idiopathic inflammatory myopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic inflammatory myopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic inflammatory myopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.